Biolex Takes Over OctoPlus’ Phase II HCV Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
For upfront and milestone payments of $149 million, Biolex assumes development costs for Locteron, an interferon alfa.
You may also be interested in...
A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.
A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.
Length Of Therapy Becomes An Issue In HCV Protease Inhibitor Race
Schering-Plough’s Phase II boceprevir data are likely to fuel the debate.